The Federal Agency for Medicines and Health Products (FAMHP) has issued a warning about fraudulent advertisements on social media promoting the sale of GLP-1 analogues, which mimic weight-loss drugs like Ozempic, Rybelsus, and Wegovy.
These counterfeit GLP-1 analogues are falsely presented as officially approved, featuring unauthorised use of logos from FAMHP, the Federal Public Service (FPS) Health, and the National Institute for Health and Disability Insurance (NIHDI).
When sold online without a prescription, such products are always falsified and pose significant health risks. These medications are legally available only by prescription and must be dispensed solely at licensed pharmacies.
Illegally sold GLP-1 analogues lack quality control, traceability, or monitoring of production, composition, and dosage. There is no guarantee of their safety, effectiveness, or quality.
In cases where these illegal products are contaminated or contain excessive concentrations of active substances, recalls cannot be initiated due to their unlawful distribution channels.
